[EN] COX-2 INHIBITING PYRIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIDINE INHIBITEURS DE LA COX-2
申请人:GLAXO GROUP LTD
公开号:WO2004024691A1
公开(公告)日:2004-03-25
Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
An efficient, one-pot methodology of direct synthesis of perylene-fused cyclicketones from perylene and 2-alkenoic acids under acidic catalytic conditions has been developed. The reaction of perylene with 2,3-disubstituted 2-alkenoic acid leads, via Friedel–Crafts acylation followed by Nazarov cyclization, to the formation of disubstituted 5,6-dihydro-4H-cyclopenta[b]perylen-4-ones in high yield (up
our reports of N‐cinnamoylated chloroquine and quinacrine analogues as promising dual‐stage antimalarial leads with high in vitro potency against both blood‐stage Plasmodium falciparum and liver‐stage Plasmodium berghei, we decided to investigate the effect of replacing the cinnamoyl moiety with otheracylgroups. Thus, a series of N‐acylated analogues were synthesized, and their activities against blood‐
Efficient synthesis of trifluoromethylated dihydrochalcones, aryl vinyl ketones and indanones by superelectrophilic activation of 4,4,4-trifluoro/3-(trifluoromethyl)crotonic acids
作者:G.K. Surya Prakash、Farzaneh Paknia、Arjun Narayanan、Golam Rasul、Thomas Mathew、George A. Olah
DOI:10.1016/j.jfluchem.2012.07.008
日期:2012.11
Superacid catalyzed electrophilic substitution of arenes using 4,4,4,-trifluoro/3-trifluoromethylcrotonic acids has been investigated. The direct synthesis of various trifluoromethylated dihydrochalcones, aryl vinyl ketones and indanones has been achieved by this methodology. It has been found that the position of the trifluoromethyl group has a profound effect on the nature of the reaction and the products
Pyridazine derivatives and their use as therapeutic agents
申请人:Chakka Nagasree
公开号:US20060009459A1
公开(公告)日:2006-01-12
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia):
where x, y, W, V, R
2
, R
3
, R
4
, R
5
, R
6
, R
6a
, R
7
, R
7a
, R
8
, R
8a
, R
9
and R
9a
are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.